Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research

Lancet Oncology

Volumn 3, Issue 10, 2002, Pages 604-610

  Kumagai, Youichi ^a   Toi, Masakazu ^a   Inoue, Haruhiro ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; RETINOID DERIVATIVE; TRYPSIN; TUMOR PROTEIN; VASCULOTROPIN; VITAMIN D;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; EARLY CANCER; ESOPHAGOSCOPY; ESOPHAGUS CANCER; HUMAN; LABORATORY TEST; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; MICROMORPHOLOGY; MICROVASCULATURE; MOLECULAR BIOLOGY; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE NEU; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0036799938     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00874-4     Document Type: Review

References (67)

1. Adachi Y, Mori M, Enjoji M, Sugimachi K. Microvascular architecture of early gastric carcinoma. Microvascular-histopathologic correlates. Cancer 1993; 72: 32-36.
2. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-98.
3. Nakagawa S, Nishimaki T, Suzuki T, et al. Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus. Surgery 2001; 129: 302-08.
4. Torres C, Wang H, Turner J, et al. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Hum Pathol 1999; 30: 753-58.
5. Koide N, Nishio, A, Kono T, et al. Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology 1999; 46: 952-58.
6. Takebayashi Y, Natsugoe S, Baba M, et al. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 1999; 85: 282-89.
7. Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195-200.
8. Uchida S, Shimada Y, Watanabe G, et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998; 77: 1704-09.
9. Takebayashi Y, Natugoe S, Baba M, et al. Angiogenesis in esophageal squamous cell carcinoma. Oncol Rep 1998; 5: 401-04.
10. Igarashi M, Dhar DK, Kubota H, et al. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998; 82: 1225-32.
11. Kuwano H, Sonoda K, Yasuda M, et al. Tumor invasion and angiogenesis in early esophageal squamous cell carcinoma. J Surg Oncol 1997; 65: 188-93.
12. Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997; 79: 220-25.
13. Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma: association with angiogenesis and tumor progression. Cancer 1997; 79: 206-13.
14. Ogata Y, Harada Y, Fujii T, et al. Immunohistochemical localization of vascular endothelial growth factor in esophageal cancer. Kurume Med J 1996; 43: 157-63.
15. Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000; 6: 1161-68.
16. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-69.
17. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg 2001; 88: 1105-09.
18. Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001; 93: 662-66.
19. Koide N, Nishio, A, Hiraguri M, et al. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma ofthe esophagus. Am J Gastroenterol 2001; 96: 1733-40.
20. Li Z, Shimada Y, Uchida S, et al. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 453-60.
21. Millikan KW, Mall JW, Myers JA, et al. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg 2000; 66: 401-06.
22. Okamoto K, Oshika Y, Fukushima Y, et al. Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189. Oncol Rep 1999; 6: 1201-04.
23. Arii S, Mori A, Uchida S, et al. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999; 12: 25-30.
24. Nagaoka H, Iino Y, Takei H, Morishita Y. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998; 13: 449-54.
25. Matsumura M, Chiba Y, Lu C, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 1998; 128: 55-63.
26. Endo M, Kawano T. Detection and classification of early squamous cell esophageal cancer. Dis Esoph 1997; 10: 155-58. 27
27. Sato F, Shimada Y, Watanabe G, et al. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 1999; 80: 1366-72.
28. Yamashita K, Mori M, Kataoka A, et al. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001; 84: 276-82.
29. Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999; 59: 3313-16.
30. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000; 88: 2201-09.
31. Yamamoto H, Iku S, Itoh F, et al. Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer 2001; 91: 1324-31.
32. Xing EP, Yang GY, Wang LD, et al. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 1999; 5: 1231-40
33. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990; 87: 9958-61.
34. Noori P, Hou SM. Mutational spectrum induced by acetaldehyde in the HPRT gene of human T lymphocytes resembles that in the p53 gene oresophageal cancers. Carcinogenesis 2001; 22: 1825-30
35. Bennett WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6092-97.
36. Shibagaki I, Tanaka H, Shimada Y, et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1995; 1: 769-73.
37. Biramijamal F, Allameh A, Mirbod P, et al. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 2001; 61: 3119-23.
38. Tanaka S, Mori M, Akiyoshi T, et al. Coexpression of Grb7 with epidermal growth factor receptor or HER2/erbB2 in human advanced esophageal carcinoma. Cancer Res 1997; 57: 28-31.
39. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-84.
40. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28: 27-32
41. Shamma A, Yamamoto H, Doki Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229-38.
42. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclo-oxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
43. Tanaka H, Kijima H, Tokunaga T, et al. Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinomas. Int J Oncol 1999; 14: 1069-73.
44. Chiarugi V, Magnelli L, Gallo O. COX-2, iNOS, and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998; 2: 715-19.
45. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001; 61: 1830-32.
46. Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA 1999; 96: 9671-76.
47. Cattaruzza M, Dimigen C, Ehrenreich H, Hecker M. Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 2000; 14: 991-98.
48. Purvis NB Jr, Giorgio TD. The effects of elongational stress exposure on the activation and aggregation of blood platelets. Biorheology 1991; 28: 355-67.
49. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140-43.
50. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
51. Aloia TA, Harpole DH Jr, Reed CE, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001; 72: 859-66.
52. Toi M, Matsumoto T, Bando, H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667-73.
53. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-85.
54. O'Brien TS, Fox SB, Dickinson AJ, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996; 56: 4799-804.
55. Fujimoto J, Sakaguchi H, Hirose R, et al. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999; 79: 1249-54.
56. Fujimoto J, Sakaguchi H, Hirose R, et al. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999; 80: 827-33.
57. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998; 4: 3017-24.
58. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 1997; 75: 477-81.
59. Inoue H, Honda T, Yoshida T, et al. Ultra-high magnification endoscopy of the normal esophageal mucosa. Dig Endosc 1996; 2: 134-38.
60. Kumagai Y, Inoue H, Nagai K, et al. Magnifying endoscopy, stereoscopic microscopy and the microvascular architecture of superficial esophageal carcinoma. Endoscopy 2002; 34: 369-75.
61. Inoue H, Honda T, Nagai K, et al. Ultra-high magnification endoscopic observation of carcinoma in situ. Dig Endosc 1997; 1: 16-18.
62. Shureiqi I, Xu X, Chen D, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 2001; 61: 4879-84.
63. Kalgutkar AS, Crews BC, Rowlinson SW, et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998; 280: 1268-70.
64. Marrogi A, Pass HI, Khan M, et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60: 3696-700.
65. Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. IntJ Cancer 2001; 93: 218-23.
66. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87: 214-20.
67. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-78.